RxDoctor Payments Data

Nicki Vogel

Nurse Practitioner · Spindale, NCNPI 1437235173

Payments from drug & device makers

$9,834in general payments, 2019–2025

Across 593 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • GSK$874
  • Pfizer$820
  • Novo Nordisk$656
  • Lilly USA, LLC$633
  • plus $5K from 36 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$9,819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,834 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$53,549
Medicare patients
199
Services billed
1,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$90,853
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$66,155
OzempicSemaglutide46$44,778
EliquisApixaban41$40,187
MounjaroTirzepatide13$28,525
RybelsusSemaglutide13$20,018
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$18,136
LinzessLinaclotide27$17,998
FarxigaDapagliflozin Propanediol18$17,907
MyrbetriqMirabegron27$11,310
XareltoRivaroxaban15$10,229
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,452
MovantikNaloxegol Oxalate13$5,083
SymbicortBudesonide/Formoterol Fumarate15$4,959
NexletolBempedoic Acid12$4,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$313$90,853118 claims
GSKTrelegy Ellipta$874$66,15571 claims
Novo NordiskOzempic, Rybelsus$656$64,79659 claims
PfizerEliquis$820$40,18741 claims
Lilly USA, LLCMounjaro$633$28,52513 claims
AstraZenecaFarxiga, Symbicort$1,004$22,86533 claims
AbbVieLinzess, Synthroid$1,004$21,87475 claims
Astellas Pharma US IncMyrbetriq$108$11,31027 claims
Johnson & JohnsonXarelto$61$10,22915 claims
Esperion Therapeutics, Inc.Nexletol$32$4,36112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Spindale

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →